Recruiting

Testing a new cell therapy after standard lymphoma treatment

Plain-English translation of NCT06500273 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing cemacabtagene ansegedleucel, a new type of cell therapy designed to fight large B-cell lymphoma. The study enrolls patients who have completed standard chemotherapy and achieved good responses, but still have tiny amounts of cancer cells detectable by a special blood test. Researchers want to see if this medication can prevent the lymphoma from returning, compared to simply watching patients closely without additional treatment.

Even when patients respond well to initial chemotherapy, some still have lingering cancer cells that can lead to relapse. This trial exists to find out whether giving this medication as a 'consolidation' treatment—right after standard chemotherapy—can eliminate those remaining cells and improve long-term survival.

Do you qualify?

You likely qualify if…

you have been diagnosed with large B-cell lymphoma and completed your first course of standard chemotherapy
your cancer responded well (complete or partial response) to that initial treatment
you have minimal residual disease detected by a special blood test (Foresight CLARITY test)
you are at least 18 years old and in generally good health
you have recovered from side effects of your previous chemotherapy to baseline or mild levels

You likely don't qualify if…

your lymphoma has involved your central nervous system or came from transformation of another cancer type
you have previously received anti-CD19 targeted therapies or other cancer treatments after your initial therapy
you have an active autoimmune disease or active serious infection requiring treatment
you have had another cancer or bone marrow disorder within the past 3 years

What participation looks like

If you join this trial, you will be randomly assigned to one of two groups: either receive the new cell therapy (which involves receiving chemotherapy drugs to prepare your body, followed by an infusion of the new cells) or be closely observed without additional treatment. Participants receiving the medication will go through a lymphodepletion regimen and then receive the cell infusion, with monitoring for safety and effectiveness. All participants will have regular follow-up visits and blood tests to track their response and watch for any side effects.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Testing a new cell therapy after standard lymphoma treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations